William Blair Has Bullish Forecast for argenex Q2 Earnings

argenex SE (NASDAQ:ARGX) – William Blair upped their Q2 2025 EPS estimates for shares of argenex in a research note issued to investors on Monday, July 14th. William Blair analyst M. Minter now expects that the company will post earnings per share of $2.90 for the quarter, up from their previous estimate of $2.36. The consensus estimate for argenex’s current full-year earnings is $3.13 per share. William Blair also issued estimates for argenex’s FY2025 earnings at $12.46 EPS and FY2026 earnings at $25.60 EPS.

Several other research analysts also recently commented on ARGX. Citigroup reissued a “buy” rating on shares of argenex in a research note on Wednesday, May 21st. Baird R W upgraded shares of argenex from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 13th. Guggenheim cut their target price on shares of argenex from $1,100.00 to $1,065.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $720.00 target price on shares of argenex in a research note on Tuesday, July 1st. Finally, Robert W. Baird upgraded shares of argenex from a “neutral” rating to an “outperform” rating and set a $680.00 price target for the company in a report on Tuesday, May 13th. Nineteen research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $728.06.

argenex Stock Up 3.9%

Shares of ARGX stock opened at $577.92 on Wednesday. The business has a fifty day simple moving average of $563.56 and a 200 day simple moving average of $600.69. The company has a market cap of $35.37 billion, a P/E ratio of 35.65, a P/E/G ratio of 1.01 and a beta of 0.37. argenex has a twelve month low of $457.42 and a twelve month high of $678.21.

argenex (NASDAQ:ARGX) last issued its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.26. argenex had a return on equity of 16.15% and a net margin of 40.20%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million.

Institutional Trading of argenex

Several institutional investors have recently added to or reduced their stakes in ARGX. GeoWealth Management LLC raised its holdings in argenex by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after purchasing an additional 18 shares during the last quarter. FIL Ltd bought a new position in argenex during the fourth quarter worth $38,000. Rakuten Securities Inc. raised its stake in argenex by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock worth $36,000 after buying an additional 22 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in argenex in the fourth quarter valued at $38,000. Finally, WPG Advisers LLC bought a new stake in argenex during the first quarter valued at $37,000. 60.32% of the stock is currently owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.